Enovis Corp Appoints Damien McDonald as CEO Effective May 2025

Enovis Corp has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025, succeeding Matt Trerotola, who is retiring. McDonald, with over 35 years of experience in the medical device industry, previously served as CEO of LivaNova and will also join the Board of Directors after the 2025 Annual Meeting. The company reaffirmed its guidance for first-quarter revenues between $555 and $563 million and adjusted EBITDA of $97 to $100 million. Sharon Wienbar, Lead Independent Director, expressed confidence in McDonald's leadership, highlighting his successful track record in enhancing growth and profitability. This leadership change is expected to bolster Enovis's competitive edge in the medical technology sector, although analysts caution about potential external risks affecting future performance. The transition plan will be discussed further in the upcoming earnings call on May 8, 2025.